Leaps by Bayer

Indapta Therapeutics is a biotechnology company focused on developing an off-the-shelf, non-engineered NK (natural killer) cell therapy platform for treating blood and solid tumor cancers. The company aims to enhance the immune response and improve antibody therapy cytotoxicity.

one.bio is a biotechnology company spun out from UC Davis that develops naturally derived oligosaccharides using proprietary technology to convert natural products into novel ingredients. The focus is on producing oligosaccharides that modulate the microbiome and immune function for applications in food, agriculture, and biopharmaceuticals. By supplying clients with novel prebiotics, symbiotics, and immunomodulatory ingredients, the company aims to support health outcomes in humans and animals. Leveraging its specialized platform, one.bio pursues ingredients that can influence gut microbiota, nutrient absorption, and immune responses, positioning itself at the intersection of nutrition and therapeutics.

Nuvig Therapeutics focuses on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function. The company is dedicated to creating a pipeline of novel immune therapeutics specifically targeting chronic inflammatory and autoimmune diseases. By harnessing natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options for patients, ultimately improving their health outcomes.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Pairwise Plants is an innovative agricultural company based in San Diego, California, focused on gene editing to enhance the quality of fruits and vegetables. Founded in 2017 by a team of experts in biotechnology and agriculture, Pairwise utilizes advanced techniques, including base editing and high-fidelity enzymes, which are licensed from renowned institutions such as Harvard and Massachusetts General Hospital. The company develops new varieties of crops, including leafy greens, berries, and stone fruits, in addition to working with traditional crops like corn, soybeans, wheat, cotton, and canola. By collaborating with food and agriculture organizations, Pairwise aims to create healthier and more sustainable produce, with initial products expected to be available in the coming years.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

Huma is a global health technology company that provides a modular platform to support digital hospitals at home across disease areas. The platform combines predictive algorithms, digital biomarkers, and real-world data to enable proactive and predictive care and research. It integrates data from hospital databases, patient wearables, and mobile devices to deliver real-time information to healthcare providers, supporting connected care. Through collaborations with leading healthcare institutes, Huma uses data and clinical expertise to measure outcomes and accelerate research and therapies, helping clinicians deliver better patient care.

Transcarent is a consumer-directed health and care platform serving employees of self-insured employers and their families. It combines software, technology, health guides, and data science to provide unbiased information, trusted guidance, and access to high-value care. The company connects users with an integrated ecosystem of high-value providers and health services, enabling customers to exercise choice and transparency for addressing a broad range of healthcare challenges.

Summer Health facilitates convenient access to high-quality healthcare professionals via text messaging. It provides expert advice and reliable answers to users' health concerns.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

9amHealth is a healthcare service provider that aims to deliver comprehensive medical support for chronic conditions such as diabetes, hypertension, and hyperlipidemia. The company offers personalized care plans, prescription medication, at-home lab tests, and unlimited virtual visits, ensuring that patients have direct access to affordable and compassionate care. By redesigning all care elements into a single digital service, 9amHealth caters to the modern realities of patients' lives, making healthcare always available and convenient, even for those without insurance. Its focus on chronic conditions highlights its commitment to improving the health and well-being of customers in the United States.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, which plays a critical role in immune-mediated inflammatory conditions. Its pipeline includes next-generation TYK2 inhibitors for treating multiple sclerosis and other neuroinflammatory diseases, as well as topical candidates for immune-mediated dermatologic conditions.

Jixing Pharmaceuticals is a global biotechnology company focused on developing and commercializing innovative therapeutics for cardiovascular and ophthalmic diseases. The company’s asset pipeline includes treatments for conditions such as hypertrophic cardiomyopathy, heart failure, presbyopia, hypertension, and dry eye disease. Jixing Pharmaceuticals has in-licensed a small molecule cardiac myosin inhibitor, designed to address the specific needs of patients suffering from hypertrophic cardiomyopathy. By providing advanced treatment options, the company aims to meet the significant unmet medical needs of patients in China and beyond, particularly those facing serious, life-threatening health challenges in the fields of cardiology and ophthalmology.

NewLeaf Symbiotics, Inc. is an agriculture technology company based in Saint Louis, Missouri, dedicated to the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on naturally occurring bacteria, particularly pink pigmented facultative methylotrophs, which are utilized across various agricultural sectors, including row crops, vegetables, fruits, and ornamental plants. NewLeaf Symbiotics conducts extensive laboratory, greenhouse, and field trials to validate the effectiveness of its products, providing farmers with sustainable solutions to combat plant diseases and improve agricultural productivity. Originally founded as TrophoMax, LLC in 2011, the company rebranded in July 2012 to better reflect its mission and objectives in the agricultural biotechnology space.

65LAB is a biotechnology company that specializes in accelerating the development of innovative therapies. It operates an accelerator program designed to commercialize promising therapeutic projects. The company identifies potential therapies from applicants, provides funding and mentoring, and helps these projects achieve preclinical proof-of-concept.

Founded in 2018, Rantizo specializes in developing and selling agricultural drones along with associated equipment such as trailers, sprayers, spreaders, batteries, and chargers. The company offers spraying services for crops using an electrostatic spraying technique, ensuring uniform coverage.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Guardian Agriculture specializes in developing electric vertical takeoff and landing (eVTOL) systems for precision crop application. Their automated, electric aerial systems enable farmers to reach areas previously inaccessible, reduce environmental impact, minimize product resistance, and optimize chemical use for sustainable farming.

ChrysaLabs develops a portable, real-time soil analysis system comprising a handheld probe that measures soil nutrients and health in the field and a management platform that lets growers and agronomists access data and take action. Founded in 2017 and based in Montreal, Canada, the company aims to help users optimize fertilizer use and improve crop yields by providing a comprehensive view of soil fertility. Its technology enables measurement of soil properties directly in the field, at any depth, with a large contact surface and without sample preparation, supporting informed decisions on nutrient management.

Andes Ag, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing microbe-based seed technologies aimed at promoting sustainable agriculture. The company leverages beneficial microbes that have naturally co-evolved with plants over millennia. Through scientific research and advanced predictive software powered by artificial intelligence, Andes creates customized microbe-based formulations designed to enhance crop yields, accelerate growth, and enable cultivation in traditionally unsuitable lands. These solutions also aim to reduce the reliance on fertilizers and pesticides, helping farmers address the challenges posed by global climate change. Andes is positioned to contribute significantly to a new green revolution, fostering responsible and environmentally friendly agricultural practices.

Fork & Good is a Brooklyn-based food company founded in 2018 that specializes in developing a new approach to food production. The company focuses on producing cultivated meat, which involves growing real meat cells to create pure animal proteins and fats that are clean, traceable, and flavorful. By emphasizing sustainability, Fork & Good aims to provide consumers with affordable and healthy food options, ensuring that its products deliver the essential nutrients while addressing the growing demand for sustainable food solutions.

Paratus Sciences focuses on advancing human health and health security by studying the biology of bats. It integrates cell biology, genomics, informatics, and large-scale data inputs to compare disease resistance patterns in bats with those in humans, aiming to develop therapeutics that mimic bats' adaptations.

EarthOptics develops a global soil cloud platform for sustainable agricultural management. It uses advanced sensors and machine learning to create accurate soil maps with fewer samples, enabling farmers to make informed decisions about soil compaction, fertility, and carbon levels.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Metagenomi is a genetic medicines company headquartered in Emeryville, California. It leverages metagenomics and machine learning to discover novel genome editing systems from diverse organisms, then convert these natural systems into compact, highly efficient, and specific tools aimed at reducing immune responses. The company maintains a proprietary, metagenomics-derived genome editing toolbox that includes programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), large template RIGS, and CRISPR-associated transposases (CASTs). Its development focus is in vivo gene editing with a wholly owned pipeline, while exploring technology out-licensing for ex vivo cell therapies to pursue curative therapeutics for genetic diseases.

Founded in 2013, Sound Agriculture develops crop enhancement products using molecular discovery. Their solutions aim to increase harvest yields, enhance water efficiency, and improve crop resilience to climate change.

NuCicer develops customized chickpea varieties to move chickpeas from an interesting ingredient to a staple superfood. Using a diverse breeding library and a proprietary platform grounded in plant genetics and machine learning, it creates chickpeas with enhanced protein content, targeted functional properties, and favorable agronomic traits. The company aims to deliver better nutrition, improved flavor, and more economical ingredients while reducing agriculture's environmental footprint. By offering multiple lines of chickpeas tailored to nutritional and environmental requirements, NuCicer supports the growth of protein-rich diets and related sectors, including plant-based foods and alternative meat.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

9amHealth is a healthcare service provider that aims to deliver comprehensive medical support for chronic conditions such as diabetes, hypertension, and hyperlipidemia. The company offers personalized care plans, prescription medication, at-home lab tests, and unlimited virtual visits, ensuring that patients have direct access to affordable and compassionate care. By redesigning all care elements into a single digital service, 9amHealth caters to the modern realities of patients' lives, making healthcare always available and convenient, even for those without insurance. Its focus on chronic conditions highlights its commitment to improving the health and well-being of customers in the United States.

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

Apollo Agriculture is an agtech company that provides smallholder farmers with access to high-quality inputs, credit, and advisory services. Using agronomic machine learning, remote sensing, and mobile technology, it assesses farmer credit risk and tailors each package to a farm’s location by integrating satellite data, soil information, farmer behavior, and crop yield models. The company delivers a bundled offer that includes financing for inputs such as fertilizer and seed, crop insurance, and ongoing consulting to improve farming decisions. Originating in Kenya with operations anchored in Nairobi, Apollo aims to expand to emerging markets and help farmers boost yields and profitability through customized credit, inputs, and advice. The approach combines modern data analytics with practical agronomy to enable farmers to adopt advanced farming methods.

Triumvira Immunologics USA, Inc. is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies aimed at improving cancer treatment outcomes. Its primary offerings include chimeric antigen receptor (CAR) therapies and engineered T cell receptor (TCR) therapies. A key aspect of Triumvira's approach is its proprietary T cell Antigen Coupler (TAC) technology, which recruits the entire natural T cell receptor and operates independently of the major histocompatibility complex (MHC). This technology enables the development of more effective therapies for a wider array of patients suffering from both solid and liquid malignancies, as well as other diseases beyond cancer.

Woebot Health is a digital mental healthcare provider that offers a platform designed to deliver personalized support and guidance. Utilizing advanced artificial intelligence and natural language processing, Woebot Health incorporates clinically proven therapeutic techniques into its services. The centerpiece of its offering is Woebot, an engaging relational agent that facilitates continuous, empathic, and user-friendly interactions. This innovative approach allows individuals and organizations to access effective mental health support seamlessly, fitting into daily life and providing help whenever needed. Woebot Health aims to enhance mental well-being through scalable digital tools, making mental health resources more accessible to a broad audience.

Vivante Health, Inc. is a digital health company focused on addressing digestive health and chronic conditions. Founded in 2016, it has developed GIThrive, a technology platform designed to provide actionable insights for managing digestive issues. GIThrive offers a comprehensive digital gut health program that includes expert guidance, 24/7 support, and personalized care plans. The company also provides GIMate, an innovative portable breathalyzer that identifies trigger foods, and GutCheck, which analyzes gut bacteria to recommend tailored diets. Vivante Health emphasizes individualized care, utilizing a scalable platform that integrates real-time data from biometric devices and partners. This approach not only aims to reduce healthcare costs and improve employee health for large employers and health plans but also enhances user empowerment through advanced science and technology. Headquartered in Houston, Texas, with an additional office in Athens, Greece, Vivante Health continues to prioritize innovative solutions in the realm of digestive health.

Indapta Therapeutics is a biotechnology company focused on developing an off-the-shelf, non-engineered NK (natural killer) cell therapy platform for treating blood and solid tumor cancers. The company aims to enhance the immune response and improve antibody therapy cytotoxicity.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Gandeeva Therapeutics is a precision biotechnology company that combines cryogenic electron microscopy (cryo-EM) and machine learning to discover and develop therapeutics by targeting and modulating key protein-protein interactions. Its structure-guided drug discovery platform comprises SPOTLIGHT for target prediction and validation, HYPERFOCUS for hit identification from virtual and fragment libraries, and CRYO-CADD for lead optimization. The company pursues a preclinical oncology program focused on difficult-to-treat cancers with novel protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area of Canada, Gandeeva aims to advance differentiated therapeutics and improve outcomes for patients by leveraging its integrated imaging, modeling, and screening capabilities.

Metagenomi is a genetic medicines company headquartered in Emeryville, California. It leverages metagenomics and machine learning to discover novel genome editing systems from diverse organisms, then convert these natural systems into compact, highly efficient, and specific tools aimed at reducing immune responses. The company maintains a proprietary, metagenomics-derived genome editing toolbox that includes programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), large template RIGS, and CRISPR-associated transposases (CASTs). Its development focus is in vivo gene editing with a wholly owned pipeline, while exploring technology out-licensing for ex vivo cell therapies to pursue curative therapeutics for genetic diseases.

Cellino develops scalable, automated biomanufacturing systems for personalized cell therapies based on induced pluripotent stem cells (iPSCs). The company aims to enable potentially curative, patient-specific treatments by producing autologous iPSCs at scale and applying AI-guided, image-driven laser processing and robotics to remove unwanted cells. By integrating image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to enhance precision, efficiency, and scalability in optical bioprocessing, accelerating the development of regenerative therapies for chronic degenerative diseases such as vision loss and Parkinson's disease.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Bloom Science is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapeutics for neurological disorders. It employs a gut-brain axis approach through its IrisRx platform to discover and design medicines from gut microbes using synthetic biology, aiming for novel biology and improved safety profiles. The company seeks to translate the therapeutic benefits associated with the ketogenic diet into medicines that treat epilepsy and other central nervous system conditions. Its pipeline encompasses therapies for Dravet syndrome and other rare epilepsies, as well as Amyotrophic Lateral Sclerosis and other neurodegenerative and cognitive disorders. Bloom Science pursues translational research to advance microbe-based therapeutics that address unmet needs in neurology. The company is headquartered in San Diego, California.

MedArrive operates a SaaS platform that connects healthcare providers with patients in their homes. Its technology integrates clinical data into electronic medical records, facilitates communication, and manages billing. By utilizing an underutilized workforce of EMS professionals, MedArrive improves patient outcomes, fosters self-advocacy, reduces costs for payers and providers, and increases access to quality healthcare.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

Zerigo Health develops innovative medical devices that deliver narrowband UVB light therapy for chronic skin conditions such as psoriasis, eczema, and vitiligo. Their flagship product, Clarify Medical, is a connected phototherapy system that enables patients to administer treatments at home under physician prescription, ensuring clinical precision while promoting convenience and empowerment.

EarthOptics develops a global soil cloud platform for sustainable agricultural management. It uses advanced sensors and machine learning to create accurate soil maps with fewer samples, enabling farmers to make informed decisions about soil compaction, fertility, and carbon levels.

Founded in 2013, Sound Agriculture develops crop enhancement products using molecular discovery. Their solutions aim to increase harvest yields, enhance water efficiency, and improve crop resilience to climate change.

Andes Ag, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing microbe-based seed technologies aimed at promoting sustainable agriculture. The company leverages beneficial microbes that have naturally co-evolved with plants over millennia. Through scientific research and advanced predictive software powered by artificial intelligence, Andes creates customized microbe-based formulations designed to enhance crop yields, accelerate growth, and enable cultivation in traditionally unsuitable lands. These solutions also aim to reduce the reliance on fertilizers and pesticides, helping farmers address the challenges posed by global climate change. Andes is positioned to contribute significantly to a new green revolution, fostering responsible and environmentally friendly agricultural practices.

Woebot Health is a digital mental healthcare provider that offers a platform designed to deliver personalized support and guidance. Utilizing advanced artificial intelligence and natural language processing, Woebot Health incorporates clinically proven therapeutic techniques into its services. The centerpiece of its offering is Woebot, an engaging relational agent that facilitates continuous, empathic, and user-friendly interactions. This innovative approach allows individuals and organizations to access effective mental health support seamlessly, fitting into daily life and providing help whenever needed. Woebot Health aims to enhance mental well-being through scalable digital tools, making mental health resources more accessible to a broad audience.

Transcarent is a consumer-directed health and care platform serving employees of self-insured employers and their families. It combines software, technology, health guides, and data science to provide unbiased information, trusted guidance, and access to high-value care. The company connects users with an integrated ecosystem of high-value providers and health services, enabling customers to exercise choice and transparency for addressing a broad range of healthcare challenges.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Founded in Berlin in 2011 by doctors, scientists, and industry pioneers, Ada Health is a global health company dedicated to creating new possibilities for personal health management. Its core system connects medical knowledge with intelligent technology to empower individuals to actively manage their health and assist medical professionals in delivering effective care.

Huma is a global health technology company that provides a modular platform to support digital hospitals at home across disease areas. The platform combines predictive algorithms, digital biomarkers, and real-world data to enable proactive and predictive care and research. It integrates data from hospital databases, patient wearables, and mobile devices to deliver real-time information to healthcare providers, supporting connected care. Through collaborations with leading healthcare institutes, Huma uses data and clinical expertise to measure outcomes and accelerate research and therapies, helping clinicians deliver better patient care.

Edifice Health is a biotechnology company spun out from Stanford University's 10-year research study on immune profiling. It offers the first biomarker composite scoring system, Inflammatory Age®, which predicts chronic diseases and provides insights to help individuals manage their aging process.

Guardian Agriculture specializes in developing electric vertical takeoff and landing (eVTOL) systems for precision crop application. Their automated, electric aerial systems enable farmers to reach areas previously inaccessible, reduce environmental impact, minimize product resistance, and optimize chemical use for sustainable farming.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

CoverCress Inc. specializes in developing and commercializing field pennycress as a sustainable oilseed crop for industrial oils and livestock feed. Founded in 2013, the company is headquartered in Saint Louis, Missouri.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Grão Direto operates a Brazilian digital marketplace that connects grain buyers and producers for agricultural commodity trading. The platform supports spot, futures, and barter transactions and provides real-time price intelligence, contract automation, and document processing to help farmers and buyers optimize deals and streamline logistics. It serves cooperatives, traders, brokers, feed factories, and warehouses, and enhances market intelligence and decision-making while supporting related processes such as logistics and financial products.

Founded in 2016, Amfora is a biotechnology company based in San Francisco. It harnesses biology to sustainably enhance the nutritional density of food and feed crops, particularly focusing on increasing protein content through gene editing. The company aims to meet global demand for high-protein foods while reducing environmental impact.

Pairwise Plants is an innovative agricultural company based in San Diego, California, focused on gene editing to enhance the quality of fruits and vegetables. Founded in 2017 by a team of experts in biotechnology and agriculture, Pairwise utilizes advanced techniques, including base editing and high-fidelity enzymes, which are licensed from renowned institutions such as Harvard and Massachusetts General Hospital. The company develops new varieties of crops, including leafy greens, berries, and stone fruits, in addition to working with traditional crops like corn, soybeans, wheat, cotton, and canola. By collaborating with food and agriculture organizations, Pairwise aims to create healthier and more sustainable produce, with initial products expected to be available in the coming years.

Ukko is a biotechnology company focused on enhancing the quality of life for individuals affected by food allergies and disorders. The company utilizes a computational engineering platform that employs artificial intelligence, immunology, and protein engineering to redesign food allergens into therapeutics that are both safe and effective. By creating a comprehensive, clinically validated map of the molecular structures associated with food allergies, Ukko reveals critical insights into the biological mechanisms governing human-food interactions. This innovative approach enables the development of new protein versions that do not provoke an immune response, providing a novel strategy for treating protein-based allergies.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Founded in 2018, Rantizo specializes in developing and selling agricultural drones along with associated equipment such as trailers, sprayers, spreaders, batteries, and chargers. The company offers spraying services for crops using an electrostatic spraying technique, ensuring uniform coverage.

Metagenomi is a genetic medicines company headquartered in Emeryville, California. It leverages metagenomics and machine learning to discover novel genome editing systems from diverse organisms, then convert these natural systems into compact, highly efficient, and specific tools aimed at reducing immune responses. The company maintains a proprietary, metagenomics-derived genome editing toolbox that includes programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), large template RIGS, and CRISPR-associated transposases (CASTs). Its development focus is in vivo gene editing with a wholly owned pipeline, while exploring technology out-licensing for ex vivo cell therapies to pursue curative therapeutics for genetic diseases.

Azitra is a clinical-stage dermatology company that leverages skin microbiome knowledge to develop novel treatments for adverse skin conditions and diseases.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that aims to radically improve patients’ lives by decoding biology through the integration of biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company operates a large-scale drug discovery platform built around Recursion OS, an infrastructure layer and a Map of proprietary biological and chemical data, supported by software tools and machine learning to explore biology beyond human bias and identify new therapeutic opportunities. Its platform includes ReChem for selecting and designing compounds, ReScreen and ReScreenRun for planning and automating large-scale experiments, and ReRun, ReAnalyze, and RePredict for digital signatures, data analysis, and predictive modeling of drug relationships. Founded in 2013, the company is based in Salt Lake City, Utah.

Triumvira Immunologics USA, Inc. is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies aimed at improving cancer treatment outcomes. Its primary offerings include chimeric antigen receptor (CAR) therapies and engineered T cell receptor (TCR) therapies. A key aspect of Triumvira's approach is its proprietary T cell Antigen Coupler (TAC) technology, which recruits the entire natural T cell receptor and operates independently of the major histocompatibility complex (MHC). This technology enables the development of more effective therapies for a wider array of patients suffering from both solid and liquid malignancies, as well as other diseases beyond cancer.

Unfold Bio, Inc. specializes in developing seeds for indoor vertical farming, offering varieties such as lettuce, spinach, cucumbers, tomatoes, and peppers. Founded in 2020 and based in Sacramento, California, the company utilizes advanced seed genetics and agronomic expertise to enhance productivity and flavor, catering to the growing vertical farming market. Its innovative approach allows for optimal water use, minimizes reliance on synthetic inputs, and facilitates food production in environments with limited arable land. Unfold collaborates with vertical farming operators, technology providers, and stakeholders across the produce supply chain to foster a sustainable local food culture. The company also conducts research and development operations in California and Singapore, aiming to improve food variety and consumer experiences in the industry.

Vesigen Therapeutics is a biotechnology company focused on delivering therapeutic payloads into intracellular targets using ARMMs (ARRDC1 Mediated Microvesicles) extracellular vesicle delivery technology. It designs and develops medicines that enable intracellular delivery and address barriers related to cell membranes and degradative systems, enabling a broad range of payloads to reach target cells. Its ARMMs platform supports delivery of RNA-based therapies, proteins, and gene-editing complexes such as Cas9/gRNA directly into the cytoplasm, expanding the universe of druggable targets and enabling new treatments for unmet medical needs. Vesigen Therapeutics aims to advance intracellular drug modalities to widen therapeutic possibilities across diseases. It was incorporated in 2020 and is based in Cambridge, Massachusetts.

Apollo Agriculture is an agtech company that provides smallholder farmers with access to high-quality inputs, credit, and advisory services. Using agronomic machine learning, remote sensing, and mobile technology, it assesses farmer credit risk and tailors each package to a farm’s location by integrating satellite data, soil information, farmer behavior, and crop yield models. The company delivers a bundled offer that includes financing for inputs such as fertilizer and seed, crop insurance, and ongoing consulting to improve farming decisions. Originating in Kenya with operations anchored in Nairobi, Apollo aims to expand to emerging markets and help farmers boost yields and profitability through customized credit, inputs, and advice. The approach combines modern data analytics with practical agronomy to enable farmers to adopt advanced farming methods.

CoverCress Inc. specializes in developing and commercializing field pennycress as a sustainable oilseed crop for industrial oils and livestock feed. Founded in 2013, the company is headquartered in Saint Louis, Missouri.

Oerth Bio LLC is a biotechnology company focused on developing innovative solutions for crop protection. Established in 2019 and based in Durham, North Carolina, the company utilizes PROTAC (proteolysis targeting chimeras) technology to create targeted protein degraders specifically for agricultural applications. This approach aims to enhance crop yields while minimizing reliance on harmful pesticides, promoting sustainable agricultural practices. Oerth Bio's technology not only contributes to healthier crops but also aligns with the growing demand for environmentally friendly farming methods.

NewLeaf Symbiotics, Inc. is an agriculture technology company based in Saint Louis, Missouri, dedicated to the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on naturally occurring bacteria, particularly pink pigmented facultative methylotrophs, which are utilized across various agricultural sectors, including row crops, vegetables, fruits, and ornamental plants. NewLeaf Symbiotics conducts extensive laboratory, greenhouse, and field trials to validate the effectiveness of its products, providing farmers with sustainable solutions to combat plant diseases and improve agricultural productivity. Originally founded as TrophoMax, LLC in 2011, the company rebranded in July 2012 to better reflect its mission and objectives in the agricultural biotechnology space.

Immunitas Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing targeted therapeutics for patients with complex cancers. Founded in 2019, the company utilizes a single-cell sequencing platform to analyze the biology of immune cells within human tumors. This innovative approach allows Immunitas to identify novel drug targets and develop key biomarkers that guide patient selection for their therapies. By emphasizing research rooted in human biology, Immunitas aims to bridge the gap between laboratory discoveries and clinical applications. The company is advancing multiple programs toward early human studies, leveraging its expertise in antibody discovery and engineering to create effective treatments that modulate identified targets.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Huma is a global health technology company that provides a modular platform to support digital hospitals at home across disease areas. The platform combines predictive algorithms, digital biomarkers, and real-world data to enable proactive and predictive care and research. It integrates data from hospital databases, patient wearables, and mobile devices to deliver real-time information to healthcare providers, supporting connected care. Through collaborations with leading healthcare institutes, Huma uses data and clinical expertise to measure outcomes and accelerate research and therapies, helping clinicians deliver better patient care.

BlueRock Therapeutics LP is a biotechnology company specializing in the development and manufacture of engineered cell therapies, focusing on neurology, cardiology, and immunology. Utilizing its CELL+GENE platform, the company aims to create induced pluripotent stem cell (iPSC) therapies to address a variety of diseases, with initial programs targeting heart muscle regeneration in patients who have experienced heart attacks or chronic heart failure. Founded in 2016 and headquartered in Cambridge, Massachusetts, BlueRock Therapeutics also maintains offices in New York and Toronto. The company provides stable master cell banks, including healthy donor cells and tools for immune evasion, facilitating the cultivation and expansion of these innovative therapies. As of late 2019, BlueRock Therapeutics operates as a subsidiary of Bayer Aktiengesellschaft.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

AgBiome is a biotechnology company that develops biological products for agriculture by leveraging the plant-associated microbiome. It identifies plant microbes with potential to improve plant health, pest resistance, and yields, using genomics and screening technologies. The company builds a microbial collection and operates a platform to discover ingredients for agriculturally relevant applications, including fungicides and other biologics that target soil-borne diseases, insects, and nematodes. Through partnerships with agricultural players, AgBiome accelerates discovery and global deployment of solutions. It is based in Durham, North Carolina, with a state-of-the-art laboratory and greenhouse facility, and has a substantial research team.

Resson is a bioinformatics and data analytics company based in Fredericton, New Brunswick, specializing in customized agriculture solutions for large corporate clients. The company employs advanced technologies such as cloud-based data processing, swarm robotics, computer vision, and machine learning to enhance agricultural productivity. Its proprietary platform, the Resson Agricultural Management and Analytics System, analyzes crop metrics to assess the health and status of crops. By providing actionable insights derived from field data, Resson enables agricultural operators to optimize their operations, improve efficiency, increase yields, and maximize profitability.

Pairwise Plants is an innovative agricultural company based in San Diego, California, focused on gene editing to enhance the quality of fruits and vegetables. Founded in 2017 by a team of experts in biotechnology and agriculture, Pairwise utilizes advanced techniques, including base editing and high-fidelity enzymes, which are licensed from renowned institutions such as Harvard and Massachusetts General Hospital. The company develops new varieties of crops, including leafy greens, berries, and stone fruits, in addition to working with traditional crops like corn, soybeans, wheat, cotton, and canola. By collaborating with food and agriculture organizations, Pairwise aims to create healthier and more sustainable produce, with initial products expected to be available in the coming years.

Joyn Bio LLC, established in 2017, is a Boston-based joint venture between Leaps by Bayer and Ginkgo Bioworks, Inc., with a plant research facility in West Sacramento, California. The company specializes in developing probiotics for plants using synthetic biology, aiming to provide cereal crops like corn, wheat, and rice with their nitrogen needs, thereby reducing agriculture's reliance on chemical fertilizers and mitigating environmental impacts. Joyn Bio's team comprises microbiologists, synthetic biologists, plant scientists, and ecologists working collaboratively to address these challenges.

NewLeaf Symbiotics, Inc. is an agriculture technology company based in Saint Louis, Missouri, dedicated to the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on naturally occurring bacteria, particularly pink pigmented facultative methylotrophs, which are utilized across various agricultural sectors, including row crops, vegetables, fruits, and ornamental plants. NewLeaf Symbiotics conducts extensive laboratory, greenhouse, and field trials to validate the effectiveness of its products, providing farmers with sustainable solutions to combat plant diseases and improve agricultural productivity. Originally founded as TrophoMax, LLC in 2011, the company rebranded in July 2012 to better reflect its mission and objectives in the agricultural biotechnology space.

FarmLead Resources Ltd. is a digital marketplace designed to enhance the buying and selling of grain, connecting farmers with verified buyers across North America. Founded in 2013 and based in Ottawa, Canada, the company operates in key agricultural regions including Alberta, Saskatchewan, Manitoba, and Ontario. Through its online platform and mobile application, FarmLead offers various services such as market research, grain testing, and price visibility, which help reduce brokerage fees and risks for farmers. The marketplace promotes efficiency, transparency, and equality within the grain industry, enabling farmers to negotiate better deals while allowing buyers to conveniently find the grain they need in their preferred locations.

BlueRock Therapeutics LP is a biotechnology company specializing in the development and manufacture of engineered cell therapies, focusing on neurology, cardiology, and immunology. Utilizing its CELL+GENE platform, the company aims to create induced pluripotent stem cell (iPSC) therapies to address a variety of diseases, with initial programs targeting heart muscle regeneration in patients who have experienced heart attacks or chronic heart failure. Founded in 2016 and headquartered in Cambridge, Massachusetts, BlueRock Therapeutics also maintains offices in New York and Toronto. The company provides stable master cell banks, including healthy donor cells and tools for immune evasion, facilitating the cultivation and expansion of these innovative therapies. As of late 2019, BlueRock Therapeutics operates as a subsidiary of Bayer Aktiengesellschaft.

Resson is a bioinformatics and data analytics company based in Fredericton, New Brunswick, specializing in customized agriculture solutions for large corporate clients. The company employs advanced technologies such as cloud-based data processing, swarm robotics, computer vision, and machine learning to enhance agricultural productivity. Its proprietary platform, the Resson Agricultural Management and Analytics System, analyzes crop metrics to assess the health and status of crops. By providing actionable insights derived from field data, Resson enables agricultural operators to optimize their operations, improve efficiency, increase yields, and maximize profitability.

Plant Response is a developer of agricultural technologies focused on enhancing plant health and growth through biological solutions. The company utilizes natural compounds to create products that improve plant immunity, increase tolerance to environmental stresses, and optimize nutrient use. By leveraging technology initially developed by researchers at the CBGP, Plant Response aims to address the challenges faced in modern agriculture and provide effective crop protection solutions. Their innovations are designed to meet the evolving needs of agricultural professionals globally, contributing to the restoration and advancement of the agricultural ecosystem.

AgBiome is a biotechnology company that develops biological products for agriculture by leveraging the plant-associated microbiome. It identifies plant microbes with potential to improve plant health, pest resistance, and yields, using genomics and screening technologies. The company builds a microbial collection and operates a platform to discover ingredients for agriculturally relevant applications, including fungicides and other biologics that target soil-borne diseases, insects, and nematodes. Through partnerships with agricultural players, AgBiome accelerates discovery and global deployment of solutions. It is based in Durham, North Carolina, with a state-of-the-art laboratory and greenhouse facility, and has a substantial research team.